Lundbeck raises 2026 outlook on strong US drug sales
Danish drugmaker H Lundbeck raised its 2026 forecasts due to strong US demand and delayed generic competition. Shares rose 4.2 percent following the report.
Xurve View
Insights:
Xurve View
H LUNDBECK A/S-A SHS raised its 2026 revenue growth forecast to 7%-9% on Tuesday midday following strong demand in the United States. Shares in the Denmark-based drugmaker rose 4.2% after it increased adjusted EBITDA growth targets to 8%-14%. Delayed generic competition for key treatments provides a longer runway for high-margin sales before patent cliffs hit.
